As of May 31, 2026, the U.S. Food and Drug Administration had received 990 adverse-event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide.
Although these reports do not prove that the medications caused every event, they highlight a growing challenge: as demand for treatments promising better health, recovery and longevity expands, patients need reliable information about what they are taking, where it comes from and what evidence supports its use.
The FDA’s safety information on unapproved GLP-1 drugs explains some of the risks associated with products that fall outside established approval pathways.
Peptides have become a prominent part of the conversation about health and human performance. They appear in discussions about muscle recovery, tissue repair, weight management, sleep, skin health and longevity.
Some peptide-based medicines have established medical uses, while others remain experimental or lack sufficient evidence to support the benefits promoted online.
Recent reporting on potential changes to access to unapproved peptides illustrates how quickly this market is evolving. Yet these very different products are often discussed as though they belong to one proven category.
That is where the problem begins.
Scientific interest is not the same as clinical proof, and a compelling personal testimonial is not a substitute for evidence that a treatment is safe and effective.
I first encountered peptides in 2008, when the conversation around them looked very different from the one we see today. Since then, I have watched interest in these compounds evolve from a relatively specialized subject into a mainstream wellness conversation.
What concerns me is not that people are curious about new approaches to health. It is that public enthusiasm can move much faster than the systems needed to assess risk, communicate uncertainty and protect patients.
The Importance of Trust
I know the consequences can be personal. I was hospitalized after using a peptide batch that I believe was contaminated. That experience fundamentally changed how I think about the products people use in pursuit of better health.
The promise of a treatment can be persuasive, particularly when someone is trying to recover from an injury, improve their quality of life or address a problem that conventional options have not resolved.
But the potential benefit means little if the substance itself cannot be trusted.
My experience is not clinical research, and it should not be interpreted as proof that every peptide product is unsafe. It is a reminder of a more basic issue: consumers cannot reliably assess the quality, purity or suitability of a substance simply by looking at its label, reading a supplier’s claims or seeing other people recommend it.
That challenge has become more urgent as the market grows. The popularity of GLP-1 medications has helped bring peptide-related treatments into everyday discussion, while social media has amplified interest in compounds promoted for benefits that may not be established by robust human studies.
A Washington Post report on the debate surrounding unapproved peptides highlights a difficult policy question: how can regulators respond to public demand without allowing enthusiasm to outpace evidence and safeguards?
Scientific Plausibility
The answer cannot be to treat every peptide as inherently dangerous. Peptides are a broad class of molecules, and their risks depend on the specific compound, its intended use, the evidence behind it, the dose, the route of administration and the quality of the product.
Some peptide-based medicines have undergone rigorous evaluation and are approved for particular indications. Others are still being studied. Many products promoted online have not been adequately evaluated for the uses being advertised.
Those differences matter. Evidence supporting one peptide for a defined medical purpose cannot automatically be transferred to another compound or a different use.
Nor does a plausible biological mechanism prove that a treatment will deliver a meaningful benefit in people.
The questions that matter are whether a product has been properly studied, what outcomes were measured, what risks were identified and whether the evidence applies to the person considering it.
The FDA’s explanation of how drugs are evaluated and approved provides useful context for understanding why scientific plausibility alone is not enough.
Not a Technicality
The regulatory position also needs to be understood clearly. The FDA explains that compounded drugs are not reviewed and approved by the agency for safety, effectiveness and quality before they are marketed.
Compounding can serve legitimate medical needs, but compounded products are not interchangeable with FDA-approved medicines simply because they contain a related active ingredient.
The agency has also warned telehealth companies about illegal marketing of compounded GLP-1 drugs, including misleading claims about their status and relationship to approved medicines.
This is not a technicality. Patients deserve to know whether a treatment is approved for their intended use, whether it is compounded, what is known about its risks and who is responsible for its preparation and oversight.
Clear information allows people to make decisions with their healthcare professionals. Ambiguous claims make that harder.
The online market for research-use-only peptides presents another concern. A disclaimer stating that a substance is intended for research does not establish that it is safe for human use.
It does not verify purity, confirm the concentration in a vial or demonstrate that the product was manufactured under appropriate conditions.
A Dangerous Gap
When substances are sold with such disclaimers but promoted through online discussions as tools for personal use, consumers can be left navigating a gap between the stated purpose of a product and the way it is actually being used.
That gap is dangerous precisely because it can look deceptively simple. A product may be packaged professionally, accompanied by laboratory terminology and recommended by someone who appears knowledgeable.
None of those features independently establishes that it is appropriate for human use. Even a laboratory test has limits: the result depends on what was tested, which methods were used and whether the sample accurately represents the product a customer receives.
Trust therefore has to be built through more than branding, testimonials or promises. It requires transparent sourcing, meaningful quality controls, accurate communication about evidence and appropriate clinical oversight.
Healthcare professionals need access to credible information so they can discuss potential benefits and risks without relying on online anecdotes.
Regulators need the authority and resources to address misleading claims and unsafe products. Researchers need time and rigorous study designs to establish which treatments work, for whom and under what conditions.
The Consumer's Role
Consumers also have a role, although they should not be expected to solve a complex quality-control problem on their own.
Before considering a peptide, they should ask what the compound is intended to do, whether that use has been studied in humans, what evidence supports the claimed benefit and what risks are known.
They should establish whether the product is approved for the intended use or is being offered under a different regulatory pathway.
They should also discuss it with a qualified healthcare professional who can consider their medical history, other medications and individual circumstances.
The FDA’s guidance on unapproved GLP-1 products provides further information on the importance of medical supervision and understanding a product’s regulatory status.
The wider industry must resist the temptation to turn uncertainty into a sales proposition. Early research can be promising without being conclusive.
A treatment can be worth studying without being ready for routine use. Being honest about those limits does not undermine innovation; it gives innovation a stronger foundation.
Responsible Oversight
The peptide conversation is unlikely to disappear. Public interest in longevity, recovery and personalized healthcare will continue, and scientific research may produce valuable treatments.
But growth alone is not progress. If the market expands without corresponding improvements in evidence, quality assurance and patient education, consumers will be left to distinguish credible medicine from unsupported claims with too little help.
We are still early in understanding what many of these compounds may offer. That makes responsible oversight more important, not less.
The next stage of this market should be judged not by how quickly new products reach consumers, but by whether people can make informed decisions and trust that the products offered to them meet appropriate standards.
Before using a peptide, speak with a qualified healthcare professional, verify the product’s regulatory status and source, and look for credible human evidence supporting the specific intended use.
Curiosity can drive medical progress, but it should never require patients to gamble with their safety.
Jeff Sakamoto is the founder and CEO of Scripts, a business serving providers in the hormone, peptide and wellness sector.
The views expressed in this article are his own.